335 related articles for article (PubMed ID: 22225836)
1. Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer.
Aleskandarany MA; Green AR; Benhasouna AA; Barros FF; Neal K; Reis-Filho JS; Ellis IO; Rakha EA
Breast Cancer Res; 2012 Jan; 14(1):R3. PubMed ID: 22225836
[TBL] [Abstract][Full Text] [Related]
2. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer.
Munzone E; Botteri E; Sciandivasci A; Curigliano G; Nolè F; Mastropasqua M; Rotmensz N; Colleoni M; Esposito A; Adamoli L; Luini A; Goldhirsch A; Viale G
Breast Cancer Res Treat; 2012 Jul; 134(1):277-82. PubMed ID: 22467243
[TBL] [Abstract][Full Text] [Related]
4. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
Kurozumi S; Matsumoto H; Hayashi Y; Tozuka K; Inoue K; Horiguchi J; Takeyoshi I; Oyama T; Kurosumi M
BMC Cancer; 2017 May; 17(1):354. PubMed ID: 28532429
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
[TBL] [Abstract][Full Text] [Related]
6. Ki-67 is a prognostic marker for hormone receptor positive tumors.
Pérez-López ME; García-Gómez J; Alves MT; Paradela A; García-Mata J; García-Caballero T
Clin Transl Oncol; 2016 Oct; 18(10):996-1002. PubMed ID: 26742937
[TBL] [Abstract][Full Text] [Related]
7. A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.
Wang Y; Yin Q; Yu Q; Zhang J; Liu Z; Wang S; Lv S; Niu Y
Breast Cancer Res Treat; 2011 Nov; 130(2):489-98. PubMed ID: 21837481
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of Ki-67 labeling indices with 3 different cutoff values, histological grade, and nuclear grade in hormone-receptor-positive, HER2-negative, node-negative invasive breast cancers.
Ono M; Tsuda H; Yunokawa M; Yonemori K; Shimizu C; Tamura K; Kinoshita T; Fujiwara Y
Breast Cancer; 2015 Mar; 22(2):141-52. PubMed ID: 23584595
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of Ki-67 in chemotherapy-naive breast cancer patients with 10-year follow-up.
Nishimiya H; Kosaka Y; Yamashita K; Minatani N; Kikuchi M; Ema A; Nakamura K; Waraya M; Sengoku N; Tanino H; Kuranami M; Watanabe M
Anticancer Res; 2014 Jan; 34(1):259-68. PubMed ID: 24403472
[TBL] [Abstract][Full Text] [Related]
10. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.
Matsubara N; Mukai H; Fujii S; Wada N
Breast Cancer Res Treat; 2013 Jan; 137(1):203-12. PubMed ID: 23184081
[TBL] [Abstract][Full Text] [Related]
11. Validation and comparison of CS-IHC4 scores with a nomogram to predict recurrence in hormone receptor-positive breast cancers.
Park YH; Im SA; Cho EY; Ahn JH; Woo SY; Kim S; Keam B; Lee JE; Han W; Nam SJ; Park IA; Noh DY; Yang JH; Ahn JS; Im YH
Oncology; 2014; 86(5-6):279-88. PubMed ID: 24903080
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women.
Ferguson NL; Bell J; Heidel R; Lee S; Vanmeter S; Duncan L; Munsey B; Panella T; Orucevic A
Breast J; 2013; 19(1):22-30. PubMed ID: 23240985
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of molecular classification of breast invasive ductal carcinoma.
Muñoz M; Fernández-Aceñero MJ; Martín S; Schneider J
Arch Gynecol Obstet; 2009 Jul; 280(1):43-8. PubMed ID: 19082617
[TBL] [Abstract][Full Text] [Related]
15. Intrinsic breast cancer subtypes defined by estrogen receptor signalling-prognostic relevance of progesterone receptor loss.
Braun L; Mietzsch F; Seibold P; Schneeweiss A; Schirmacher P; Chang-Claude J; Peter Sinn H; Aulmann S
Mod Pathol; 2013 Sep; 26(9):1161-71. PubMed ID: 23558572
[TBL] [Abstract][Full Text] [Related]
16. CKAP2 (cytoskeleton-associated protein2) is a new prognostic marker in HER2-negative luminal type breast cancer.
Sim SH; Bae CD; Kwon Y; Hwang HL; Poojan S; Hong HI; Kim K; Kang SH; Kim HS; Um TH; Park IH; Lee KS; Jung SY; Lee S; Kang HS; Lee ES; Kim MK; Hong KM; Ro J
PLoS One; 2017; 12(8):e0182107. PubMed ID: 28771517
[TBL] [Abstract][Full Text] [Related]
17. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
Yan J; Liu XL; Han LZ; Xiao G; Li NL; Deng YN; Yin LC; Ling LJ; Yu XY; Tan CL; Huang XP; Liu LX
Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532
[TBL] [Abstract][Full Text] [Related]
18. Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse.
Cancello G; Maisonneuve P; Rotmensz N; Viale G; Mastropasqua MG; Pruneri G; Montagna E; Iorfida M; Mazza M; Balduzzi A; Veronesi P; Luini A; Intra M; Goldhirsch A; Colleoni M
Ann Oncol; 2013 Mar; 24(3):661-8. PubMed ID: 23022996
[TBL] [Abstract][Full Text] [Related]
19. St Gallen molecular subtypes in primary breast cancer and matched lymph node metastases--aspects on distribution and prognosis for patients with luminal A tumours: results from a prospective randomised trial.
Falck AK; Fernö M; Bendahl PO; Rydén L
BMC Cancer; 2013 Nov; 13():558. PubMed ID: 24274821
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
